- Imported chemotherapy drugs are proving ineffective for most breast cancer patients in Pakistan, according to a study by the Jamilur Rahman Centre for Genomic Research at the University of Karachi.
- Genetic differences, improper drug storage, late-stage diagnoses, and a lack of personalized treatment contribute to the failure of chemotherapy.
- Experts urge immediate investment in pharmacogenomics, quality control, and advanced treatments to improve cancer care in Pakistan.
A groundbreaking study conducted by the Jamilur Rahman Centre for Genomic Research at the University of Karachi has revealed that imported chemotherapy drugs used to treat cancer, particularly breast cancer, have been found ineffective in most cases. This alarming discovery raises serious concerns about the effectiveness of existing treatment protocols and the need for alternative solutions tailored to Pakistani patients.
A Harsh Reality: Ineffective Cancer Treatment
Breast cancer remains the most prevalent form of cancer among women in Pakistan, with thousands of new cases emerging every year. However, despite the availability of chemotherapy treatments, the latest research suggests that a significant portion of these drugs is failing to deliver the expected results. The study highlights that patients undergoing chemotherapy with imported drugs are not responding as effectively as they should, resulting in poor survival rates and increased recurrence of the disease.
The University of Karachi researchers conducted a detailed analysis of the response rates of commonly used chemotherapy drugs. The findings indicate that a large percentage of patients do not experience significant tumor shrinkage, while others suffer severe side effects without notable improvements in their condition.
Possible Reasons Behind the Drug Failure
The study points to multiple factors contributing to the ineffectiveness of chemotherapy drugs in Pakistan:
-
Genetic Variability: Pakistani women may have distinct genetic profiles that make them less responsive to standard chemotherapy drugs developed based on Western genetic models. The lack of pharmacogenomic studies in Pakistan has led to a one-size-fits-all approach in cancer treatment, which may not be effective for all patients.
-
Drug Quality and Storage Issues: Experts believe that imported chemotherapy drugs may lose their efficacy due to improper storage and transportation conditions. The study raises concerns about whether these drugs maintain their potency when they finally reach hospitals and clinics.
-
Delayed Diagnosis: Breast cancer in Pakistan is often diagnosed at a later stage due to a lack of awareness and screening programs. As a result, chemotherapy treatments, which may work better in early-stage cancer, are less effective when administered at advanced stages.
-
Over-Reliance on Standard Chemotherapy: Pakistan’s healthcare system has long depended on generic chemotherapy drugs, rather than targeted or personalized treatments that consider individual patient profiles. Newer targeted therapies and immunotherapy options remain inaccessible to many due to high costs and lack of government support.
The Call for Urgent Reform
The findings from this study emphasize the need for Pakistan to shift towards personalized cancer treatments. Instead of relying solely on imported chemotherapy drugs, experts suggest investing in localized research to develop therapies suited to Pakistani genetic variations.
What’s Next for Cancer Treatment in Pakistan?
In light of these findings, oncologists and policymakers must take immediate action by:
- Enhancing Pharmacogenomic Research: Establishing genetic studies to determine which chemotherapy drugs are most effective for local populations.
- Ensuring Drug Quality Control: Strengthening regulations for imported chemotherapy drugs to maintain their potency and effectiveness.
- Improving Early Detection and Screening Programs: Encouraging routine breast cancer screenings to diagnose cases at an early stage when treatments are more effective.
- Investing in Advanced Treatments: Exploring targeted therapies, immunotherapies, and locally produced cancer drugs that could be more effective for Pakistani patients.
Conclusion
The study from Jamilur Rahman Centre for Genomic Research at the University of Karachi serves as a wake-up call for Pakistan’s healthcare system. If cancer treatments continue to be ineffective, thousands of lives will remain at risk. It is time for policymakers, researchers, and healthcare providers to come together and revolutionize cancer treatment in Pakistan by ensuring patients receive therapies that actually work for them.
Stay tuned to wow360.
